Evidences showed a link between statins and new-onset diabetes and large clinical trials in type 2 diabetes (T2DM) suggested a mild glycemic progression in statin treated. An epidemiologic analysis of the UKPDS results showed a significant correlation between glycemic control and microvascular and cardiovascular disease risk and mortality rates. They used the SMBG data from 470 of the ADAG study participants (237 with type 1 diabetes and 147 with type 2 diabetes) to determine the average fasting, premeal, 90-min postmeal, and bedtime blood glucose (BG) for predefined target HbA1c groups between 5.5 and 8.5% (37–69 mmol/mol). Previously, target blood glucose levels – as measured by the A1C, a test that reflects average blood glucose levels over several months – could be as high as 8.5 percent for children under 6 years of age, 8.0 percent for children 6-12 years of age and 7.5 for adolescents under the Association’s guidelines. If, on the other hand, glucose levels fall below the target range, symptoms of hypoglycaemia may occur. Overall, a small increase in median and mean HbA1c values was observed. Moreover, adequate guidance with regard to individualized BP targets remains to be established [6,7].
The six outcome areas thus refer to the combined effect of Mindex and Moutcome. The third subgroup (5 %) showed hyperglycemia and a delayed response without reaching the recommended HbA1c target.